Low dose G-FLIP plus mitomycin C for stage IV pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of low-dose chemotherapy drugs (G-FLIP and mitomycin C) for people with stage IV pancreatic cancer that has stopped responding to the first treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV pancreatic cancer that has spread to other parts of the body.
- Your first round of chemotherapy must have stopped working.
- You should be able to take care of yourself (ECOG score 0 to 2) and have a life expectancy of more than 3 months.
- Your major organs (like liver, kidneys, and bone marrow) must be working well enough, based on blood tests.
- You must be 18 years or older and willing to sign a consent form.
- You cannot have brain metastases, serious heart problems, or other uncontrolled diseases, and if you are able to become pregnant, you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a combination of immunotherapy, a blood-vessel/immune signal blocker, and chemotherapy for people with metastatic pancreatic adenocarcinoma. It may help shrink tumors and improve control of the disease.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.